CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 48 enrolled
Drug / intervention
Tandem t:slim X2 with Control-IQ Technology + Dexcom G6 +2 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03369067
NCT03369067N/ACompleted

Real-Time Monitoring and Glucose Control During Winter-Sport Exercise in Youth With Type 1 Diabetes: The AP Ski Camp Continued

University of Virginia·interventional·Posted Dec 11, 2017·Updated Oct 1, 2024

In Brief

A clinical study evaluating Tandem t:slim X2 with Control-IQ Technology + Dexcom G6, Dexcom CGM G5, and 1 other intervention for Type 1 Diabetes Mellitus. Completed, enrolled 48 participants across 3 sites.

Detailed Summary

An early feasibility study that will test the efficacy of the Tandem t:slim X2 with Control-IQ and Dexcom Continuous Glucose System G6 in a winter/ski camp environment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedDec 11, 2017
Enrollment StartDec 18, 2017
Primary CompletionApr 15, 2018
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 8.6 years ago

Interventions

Tandem t:slim X2 with Control-IQ Technology + Dexcom G6device

Subjects will use the Tandem t:slim X2 with Control-IQ Technology and Dexcom G6 CGM to control their glycemia. The Tandem t:slim X2 with Control-IQ device is an automated insulin delivery pump that automatically adjusts insulin delivery to predicted and prevailing glucose levels, as measured by a Dexcom G6 continuous glucose monitor \[CGM\].

Dexcom CGM G5device

The Dexcom G5 CGM is a subcutaneous glucose sensor that provides an estimate of the prevailing blood glucose concentration approximately every 5 minutes.The Dexcom G5 sensor alerts the user if the prevailing glucose concentration is higher or lower than predetermined thresholds, or if it is changing too fast. In addition, the Share/Follow functionality of the Dexcom G5 allows up to 5 people ("followers") to receive in real-time information about the current blood glucose concentration and rate of change. The Dexcom G5 system will be used by participants and clinical study staff to monitor glucose levels 24h/day during the camp, ensure participants safety, and compute glycemic control outcomes

Continuous Subcutaneous Insulin Infusiondevice

Subjects will use a subcutaneous pump to deliver insulin and control their glycemia.